ANAHYDRET and PT-1 randomized controlled trials of anagrelide versus hydroxyurea for the treatment of essential thrombocythemia.
| . | ANAHYDRET trial37 . | PT-1 trial36 . |
|---|---|---|
| AN indicates anagrelide; HU, hydroxyurea; MF, myelofibrosis. | ||
| *82.2% of patients met WHO 2001 diagnostic criteria for ET | ||
| Diagnosis | WHO criteria (2001) Central review of histology* | PVSG criteria Diagnosis by treating physician |
| Patients | High risk Treatment naïve | High risk Treated or untreated |
| Median age: AN/HU | 58/56 | 61/62 |
| Patient number: AN/HU | 122/136 | 405/404 |
| Follow-up, patient-years | 539 | 2653 |
| Total events: | ||
| Arterial thrombosis | 10 | 54 |
| Venous thrombosis | 7 | 17 |
| Hemorrhage | 6 | 30 |
| Transformation to MF | 0 | 21 |
| . | ANAHYDRET trial37 . | PT-1 trial36 . |
|---|---|---|
| AN indicates anagrelide; HU, hydroxyurea; MF, myelofibrosis. | ||
| *82.2% of patients met WHO 2001 diagnostic criteria for ET | ||
| Diagnosis | WHO criteria (2001) Central review of histology* | PVSG criteria Diagnosis by treating physician |
| Patients | High risk Treatment naïve | High risk Treated or untreated |
| Median age: AN/HU | 58/56 | 61/62 |
| Patient number: AN/HU | 122/136 | 405/404 |
| Follow-up, patient-years | 539 | 2653 |
| Total events: | ||
| Arterial thrombosis | 10 | 54 |
| Venous thrombosis | 7 | 17 |
| Hemorrhage | 6 | 30 |
| Transformation to MF | 0 | 21 |